These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21203568)

  • 1. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
    Neff CP; Ndolo T; Tandon A; Habu Y; Akkina R
    PLoS One; 2010 Dec; 5(12):e15257. PubMed ID: 21203568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
    Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R
    PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
    Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
    Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New antiretroviral drug classes in HIV therapy].
    Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
    MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
    [No Abstract]   [Full Text] [Related]  

  • 5. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
    J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
    Armstrong-James D; Stebbing J; Scourfield A; Smit E; Ferns B; Pillay D; Nelson M
    Antiviral Res; 2010 May; 86(2):224-6. PubMed ID: 20211653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
    Moreno Cuerda VJ; Rubio García R; Barros Aguado C; Morales Conejo M
    Rev Clin Esp; 2008 Oct; 208(9):463-6. PubMed ID: 19000475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
    Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].
    Katanaga H
    Nihon Naika Gakkai Zasshi; 2009 Nov; 98(11):2802-8. PubMed ID: 22462133
    [No Abstract]   [Full Text] [Related]  

  • 14. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.
    Kovarova M; Swanson MD; Sanchez RI; Baker CE; Steve J; Spagnuolo RA; Howell BJ; Hazuda DJ; Garcia JV
    J Antimicrob Chemother; 2016 Jun; 71(6):1586-96. PubMed ID: 27002074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
    Pau AK; Penzak SR; Boyd SD; McLaughlin M; Morse CG
    Pharmacotherapy; 2012 Jan; 32(1):e1-6. PubMed ID: 22392831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
    Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
    Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.
    Veselinovic M; Yang KH; Sykes C; Remling-Mulder L; Kashuba AD; Akkina R
    Virology; 2016 Feb; 489():173-8. PubMed ID: 26771889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
    Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.